Johnson & Johnson
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson CARVYKTI (ciltacabtagene autoleucel) by Quarter
CARVYKTI (ciltacabtagene autoleucel) — U.S. sales ($M) ($M)
Johnson & Johnson CARVYKTI (ciltacabtagene autoleucel): $472M in Q3 2026, up 19.2% from a year earlier. That is the highest of the 19 quarters on record here.
Where the Q3 2026 figure comes from
Source: Form 10-Q (filed 2026-10-21) ↗
Reported in Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | CARVYKTI (ciltacabtagene autoleucel) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 472 | +19.2% | Form 10-Q (filed 2026-10-21) ↗ |
| Q2 2026 | Jun 28, 2026 | 472 | +31.8% | Form 10-Q (filed 2026-07-23) ↗ |
| Q1 2026 | Mar 29, 2026 | 433 | +36.2% | Form 10-Q (filed 2026-04-22) ↗ |
| Q4 2025 | Dec 28, 2025 | 420 | +38.2% | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2025 | Sep 28, 2025 | 396 | +53.5% | Form 10-Q (filed 2026-10-21) ↗ |
| Q2 2025 | Jun 29, 2025 | 358 | +114.4% | Form 10-Q (filed 2026-07-23) ↗ |
| Q1 2025 | Mar 30, 2025 | 318 | +127.1% | Form 10-Q (filed 2026-04-22) ↗ |
| Q4 2024 | Dec 29, 2024 | 304 | +109.7% | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2024 | Sep 29, 2024 | 258 | +84.3% | Form 10-Q (filed 2025-10-22) ↗ |
| Q2 2024 | Jun 30, 2024 | 167 | +46.5% | Form 10-Q (filed 2025-07-24) ↗ |
| Q1 2024 | Mar 31, 2024 | 140 | +100.0% | Form 10-Q (filed 2025-04-23) ↗ |
| Q4 2023 | Dec 31, 2023 | 145 | +168.5% | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2023 | Oct 1, 2023 | 140 | +154.5% | Form 10-Q (filed 2024-10-23) ↗ |
| Q2 2023 | Jul 2, 2023 | 114 | +375.0% | Form 10-Q (filed 2024-07-25) ↗ |
| Q1 2023 | Apr 2, 2023 | 70 | – | Form 10-Q (filed 2024-05-01) ↗ |
| Q4 2022 | Jan 1, 2023 | 54 | – | Form 10-K (filed 2025-02-13) ↗ |
| Q3 2022 | Oct 2, 2022 | 55 | – | Form 10-Q (filed 2023-10-27) ↗ |
| Q2 2022 | Jul 3, 2022 | 24 | – | Form 10-Q (filed 2023-07-31) ↗ |
| Q1 2022 | Apr 3, 2022 | 0 | – | Form 10-Q (filed 2023-04-28) ↗ |
Breakdown
What makes up CARVYKTI (ciltacabtagene autoleucel)
Cite this data
StockData. (2026). Johnson & Johnson CARVYKTI (ciltacabtagene autoleucel) ($M), quarterly Q1 2022–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-carvykti-us
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.